2026-02-24
GLP-1 Agonists and Aging: Metabolic Benefits, Cardiovascular Evidence, and Longevity Implications
GLP-1 receptor agonists like semaglutide have demonstrated cardiovascular and metabolic benefits beyond weight reduction. This review covers the mechanistic basis, major trial evidence, and the open questions about their role in longevity medicine.
2026-02-23
Blood Sugar and Insulin Resistance: Supplement Protocol, Monitoring, and Evidence Summary
Insulin resistance precedes type 2 diabetes by years and independently drives cardiovascular risk, cognitive decline, and accelerated aging. Berberine, magnesium, alpha-lipoic acid, and chromium have the best evidence among supplements. This protocol integrates the strongest interventions with clear monitoring markers.
2026-02-21
Longevity Protocol for Women Over 50: Evidence-Based Priorities
Perimenopause and post-menopause mark a major metabolic and hormonal inflection point. This protocol covers the highest-leverage interventions for women over 50, grounded in current evidence.
2026-02-20
Berberine for Fatty Liver Risk (MASLD): Human Trial and Meta-Analysis Update
Evidence from randomized studies suggests berberine can improve liver fat-related markers in selected metabolic-risk groups, but protocol quality and baseline risk drive response.
2026-02-20
Liver Enzyme Elevation Risk: Silymarin, NAC, and Berberine With Lifestyle First
Elevated liver enzymes improve most with weight, glucose, and alcohol correction. Silymarin, NAC, and berberine can be adjuncts in selected metabolic-risk contexts.